Back to Search
Start Over
Crizotinib in
- Source :
- Clinical cancer research : an official journal of the American Association for Cancer Research. 25(24)
- Publication Year :
- 2019
-
Abstract
- Patients with pretreated advanced NSCLC and evidence ofFrom December 2014 to March 2017, 505 patients were screened and a total of 52 patients (26 patients per cohort) were enrolled onto the study. At data cutoff of September 2017, in cohort A, objective response rate was 65%, and median progression-free survival and overall survival were 22.8 months [95% confidence interval (CI) 15.2-30.3] and not reached, respectively. In cohort B, objective response rate was 27%, median progression-free survival was 4.4 months (95% CI 3.0-5.8), and overall survival was 5.4 months (95% CI, 4.2-6.5). No difference in any clinical endpoint was observed betweenCrizotinib induces response in a fraction of
- Subjects :
- Adult
Aged, 80 and over
Gene Rearrangement
Male
Salvage Therapy
Lung Neoplasms
Middle Aged
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-met
Prognosis
Survival Rate
Crizotinib
Drug Resistance, Neoplasm
Carcinoma, Non-Small-Cell Lung
Proto-Oncogene Proteins
Humans
Female
Prospective Studies
Protein Kinase Inhibitors
Aged
Subjects
Details
- ISSN :
- 15573265
- Volume :
- 25
- Issue :
- 24
- Database :
- OpenAIRE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Accession number :
- edsair.pmid..........edc2c34ce293d42ca1dd47cd9a55cb6f